The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established

Qlife Holding has extended its non-binding Letter of Intent with Hipro Biotechnology and the exclusivity period to 31 December 2026, with the reverse-takeover remaining conditional on signing a share purchase agreement by that date and the valuation to be re-evaluated once a revised transaction structure is agreed. Nasdaq Stockholm has notified the companies it will not approve the originally contemplated 'Red Chip' structure, prompting Qlife and Hipro to explore alternative deal structures and to accelerate commercial and operational collaboration in the near term via an exclusive agreement. The regulator-driven setback is likely to delay the transaction and could affect timing and valuation, while both parties continue to pursue joint value creation pending a revised framework.

Analysis

Qlife Holding AB has extended its non-binding Letter of Intent with Hipro Biotechnology to 31 December 2026 and reiterated that the reverse takeover remains conditional on signing a share purchase agreement by that date; the companies first announced the Transaction on 5 June 2025 and previously extended exclusivity to 31 December 2025 on 5 October 2025. Nasdaq Stockholm has informed the parties it will not approve the originally contemplated "Red Chip" structure (communication referenced 14 November 2025), prompting re-evaluation of the transaction structure and the valuation term once a revised framework is agreed.

In response, Qlife and Hipro say they will accelerate an exclusive commercial agreement to deepen collaboration and realize near-term business and operational synergies, but this commercial path does not remove the need for a new regulatory-compliant deal structure. The regulatory rejection creates a clear timing and valuation risk: the Transaction is likely to be delayed, valuation will be revisited, and market sentiment is labeled mildly negative and uncertain in the accompanying signals.

Key items for investors to monitor are formal Nasdaq guidance on acceptable structures, milestone delivery under the exclusive commercial agreement (revenue or partnership metrics), and whether a share purchase agreement is signed by the revised 31 December 2026 deadline, as these will determine whether value creation is operational or contingent on a restructured M&A outcome.

Key Decisions for Investors

• Pause material increases to QLIFE positions until the parties disclose a revised transaction structure and valuation or a share purchase agreement is signed by 31 December 2026
• Monitor near-term catalysts: formal Nasdaq feedback on acceptable structures, concrete KPIs from the exclusive commercial agreement, and any timetable for a new SPA, and reassess on each milestone
• Consider hedging or reducing exposure given the regulatory setback and mildly negative sentiment, or add selectively only if the commercial agreement delivers demonstrable revenue/operational progress